In this Director’s message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression.
| Read the Director's Message |
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario